Deals

Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines

Eli Lilly is diving into the messenger RNA arena, signing off on a heavily back-ended $1.8 billion deal with Germany’s CureVac to develop up to 5 new-wave cancer vaccines.

CureVac is getting $100 million in cash to kick off the collaboration, split between an upfront payment and equity stake. Then there’s a package of $1.7 billion in milestones on the table.

In turn CureVac will be tasked with designing a slate of new cancer vaccines that uses mRNA tech to instruct the human immune system to target a specific set of neoantigens. While past cancer vaccines have generally proven to be ineffective though safe, a number of developers have been hunting down specific patient antigens that can be leveraged for much more precise targeting — with a greater likelihood of success.

Ingmar Hoerr

CureVac, though, has met with a key failure on the cancer vaccine earlier in the year. Its leading mRNA program CV9104, a prostate cancer vaccine, failed a critical Phase IIb study in January. That drug used a group of “shared” antigens common to prostate cancer, while rival Moderna has been going after a more personalized approach in its program, partnered with Merck.

CureVac — backed by German billionaire Dietmar Hopp along with additional funding from the Gates Foundation — is one of the leaders in the mRNA field, with Moderna and others engaged in a scientifically demanding approach to instructing targeted cells to create a treatment. It’s still early days, though we are beginning to see more early human data that underscores the potential of the field.

For Lilly, this is another example of a more expansive approach to partnering and external innovation, with new CEO Dave Ricks more likely to reach out to collaborators than his predecessor John Lechleiter.

Noted CureVac CEO Ingmar Hoerr:

This new collaboration with Lilly is a testimony to the progress and sophistication of CureVac’s RNActive technology and the potential of mRNA-based therapeutics. We now have the opportunity to combine forces to further expand the exciting space of immuno-oncology with the next generation of cancer therapies.


The Eli Lilly and Co corporate headquarters is pictured April 26, 2017, in Indianapolis. AP Photo/Darron Cummings


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->